Dyslipidemia Market Anticipated to Witness Massive Growth with a Tremendous CAGR of % in the 7MM for the Study Period of 2018-30 | DelveInsight

DelveInsight’s Dyslipidemia Market Insights report proffers a detailed comprehension of Dyslipidemia market size by treatment, epidemiology, emerging therapies, Dyslipidemia market share of the individual therapies, current and forecasted Dyslipidemia market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).

Some of the salient features from the Dyslipidemia Market Report: 

• As per DelveInsight estimates, the Dyslipidemia market size was USD million in 2020 in the 7MM and is expected to grow at a CAGR of % for the study period 2018-2030.
• DelveInsight’s analysts estimate that the Dyslipidemia market is expected to show positive growth, mainly attributed to the increase in the prevalence of Dyslipidemia and the anticipated launch of novel therapies during the forecast period.
• Key pharmaceutical companies in the Dyslipidemia market such as Kowa, Pfizer, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Eli Lilly and Company, AstraZeneca, EMS under NC Farma, among other Dyslipidemia companies are proactively working to change the dynamics of the market.
• The Dyslipidemia pipeline therapies include Pemafibrate (K-877), Parexel, ARO-ANG3, Gemcabene, Vupanorsen (formerly known as AKCEA-ANGPTL3-LRx), AZD8233, LY3475766, Cipros 10 association, and others that are expected to launch in the study period 2018-30.
• According to DelveInsight analysis, the increase in Dyslipidemia market size is a direct outcome related to the increasing prevalent population of Dyslipidemia, and the expected launch of emerging drugs in the 7MM.

For further information on Market Impact by Therapies, Download Dyslipidemia Market sample @ Dyslipidemia Market Scenario

Dyslipidemia Overview

Dyslipidemia is a condition caused by the abnormal fluctuation in the levels of cholesterol as well as lipoproteins such as High-Density Lipoprotein (HDL) and Low-Level Lipoprotein (LDL). Besides tagging them as an important component of the living cells, their existence in escalated levels can increase the risk of getting a heart attack or any other major health issue. Dyslipidemia is segmented into two major types on the basis of their causes known as Primary Dyslipidemia and Secondary Dyslipidemia

Dyslipidemia Epidemiology Segmentation

Kindly provide some epidemiology details.

The Dyslipidemia Market report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:

• Total Prevalent Cases of Dyslipidemia
• Total Diagnosed Cases of Dyslipidemia
• Age-Specific Cases of Dyslipidemia
• Gender-Specific Cases of Dyslipidemia
• Treated Cases of Dyslipidemia

Dyslipidemia Pipeline Therapies and Key Companies

• Pemafibrate (K-877): Kowa Company
• ARO-ANG3: Arrowhead Pharmaceuticals
• Vupanorsen: Pfizer
• Gemcabene: NeuroBo Pharmaceuticals
• AZD8233: AstraZeneca
• LY3475766: Eli Lilly and Company
• Cipros 10 association: EMS under NC Farma

To know about more pipeline therapies under different development phases visit @ Dyslipidemia Pipeline Assessment, Patient Pool, and Emerging Therapies 

Dyslipidemia Market Landscape

Dyslipidemia prevention, as well as Dyslipidemia treatment, should be considered as an integral part of individual cardiovascular prevention interventions, which should be addressed primarily to those at higher risk who benefit most. To date, statins remain the first-choice therapy, ezetimibe, fibrates (fenofibrate, bezafibrate, ciprofibrate, and gemfibrozil), and nicotinic acid (niacin, also called vitamin B3, PP) represent the second-choice drugs. In addition, anti-PCSK9 drugs (evolocumab, alirocumab, and inclisiran) provide an effective solution for patients with familial hypercholesterolemia (FH) and statin intolerance at very high cardiovascular risk. Another class of drugs includes bile acid-binding resins (including cholestyramine, colesevelam, and colestipol) are orally administered anion-exchange resins that are neither absorbed systemically nor metabolized by digestive enzymes.

A robust pipeline in the Dyslipidemia treatment landscape is indicative of the very high market potential of Dyslipidemia drugs, this includes pipeline drugs like Pemafibrate (K-877) is being developed by the Kowa Company is a selective Peroxisome Proliferator-Activated Receptors (PPARs) modulator. Pemafibrate is currently undergoing Phase III (NCT04716595) trial to assess its ability to improve patients’ health. AstraZeneca in collaboration with Parexel is developing AZD8233 which is currently in Phase II of clinical trials. Another major anticipated Dyslipidemia drug in the pipeline is ARO-ANG3, it is an investigational agent from Arrowhead Pharmaceuticals, it belongs to the class of Antihyperlipidemic which is in Phase II (NCT04832971) developmental stage. Also, Eli Lilly and Company’s investigational candidate for Dyslipidemia is  LY3475766 which is currently in Phase I stage of clinical trials.

A robust pipeline of novel and emerging therapies, increasing global geriatric population, increase in the prevalence of lifestyle-related (obesity) and cardiovascular disorders serve as major aspects for Dyslipidemia market growth in the upcoming years. The increase in the Dyslipidemia market is a direct outcome related to the increasing Dyslipidemia prevalent population and the anticipated launch of emerging  Dyslipidemia drugs in the coming years. 

On the contrary, the unreported and undiagnosed Dyslipidemia cases, a significant proportion of treated patients do not reach the recommended treatment goal and an increase in the availability of generic drugs can be considered some of the potential drawbacks of the Dyslipidemia market.

Know which therapy is expected to score the touchdown first @ Dyslipidemia Market Landscape and Forecast

Scope of the Dyslipidemia Report 

• Study Period: 2018-30
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Dyslipidemia Companies:  Kowa, Pfizer, Arrowhead Pharmaceuticals, NeuroBo Pharmaceuticals, Eli Lilly and Company, AstraZeneca, EMS under NC Farma
• Key  Dyslipidemia Pipeline Therapies: Pemafibrate (K-877), Parexel, ARO-ANG3, Gemcabene, Vupanorsen (formerly known as AKCEA-ANGPTL3-LRx), AZD8233, LY3475766, Cipros 10 association
• Dyslipidemia Therapeutic Assessment:  Dyslipidemia current marketed and emerging therapies
• Dyslipidemia Market Dynamics:  Dyslipidemia market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Unmet Needs
• KOL’s views
• Analyst’s views
• Market Access and Reimbursement

Table of Contents 

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Kunjika Agarwal
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dyslipidemia-market